Biotech Sees Massive Buying Pressure Following Phase 2 Preliminary Data
August 13 2024 - 10:50AM
AllPennyStocks.com
A California-based biotech company is finding
early success on Tuesday after the company announced positive
preliminary data of Vebreltinib in patients with non-CNS met
fusion...
To read the full story on AllPennyStocks.com, click
here.
Apollomics (NASDAQ:APLM)
Historical Stock Chart
From Oct 2024 to Nov 2024
Apollomics (NASDAQ:APLM)
Historical Stock Chart
From Nov 2023 to Nov 2024